Urology Medical News about Renal cancer, bcl2 -938CC genotype

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer
The Journal of Urology, 07/24/09

Hirata H et al. - In a study to investigate the polymorphism at the bcl2 -938C/A site and its effects on clinical characteristics in pts with renal cell carcinoma (RCC), it was found that the bcl2 -938C/C genotype has worse prognosis and lower survival in pts with RCC. The bcl2 -938C/A single nucleotide polymorphism was shown to be an independent adverse prognostic factor for RCC.

Methods

The bcl2-938C/A single nucleotide polymorphism was genotyped in 216 pts with RCC, and in 209 healthy age- and gender-matched controls.
The relationship between the bcl2 -938C/A polymorphism, Bcl2 expression, proliferation, and apoptosis status were investigated in RCC tissues using immunohistochemistry and TUNEL assay.
Association of the bcl2 -938C/A single nucleotide polymorphism with survival in pts with RCC was analyzed by Kaplan-Meier curves.

Results

Survival in Bcl2-positive cases was significantly longer than in negative cases.
On univariate and multivariate analyses, the bcl2 -938CC genotype was independently associated with poor prognosis.
Kaplan-Meier analysis showed that survival in pts with CC genotypes was significantly worse than in those with CA+AA genotypes.
CC genotype carriers had significantly lower Bcl2 expression and higher proliferative activity in renal cancer tissues than CA+AA genotype carriers.

<< Previous
Endoscopic injection of submucosal bulking agents for the...

Next >>
EUS-guided fiducial placement before targeted radiation therapy...

Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09 Relevance Score: 68%

A prospective study of lifetime physical activity and prostate cancer incidence and mortality
British Journal of Cancer, 11/02/09 Relevance Score: 67%

Incidence of Cancer in Finnish Families with Clinically Aggressive and Nonaggressive Prostate Cancer
Cancer Epidemiology, Biomarkers & Prevention, 10/27/09 Relevance Score: 67%

Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer
Expert Review of Anticancer Therapy, 10/21/09 Relevance Score: 67%

The Expression of Thrombospondin-1 and p53 in Clear Cell Renal Cell Carcinoma: Its Relationship to Angiogenesis, Cell Proliferation and Cancer Specific Survival
The Journal of Urology, 10/14/09 Relevance Score: 67%